Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Analgesia and Pain Management01:25

Analgesia and Pain Management

Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
Opioid Analgesics: Synthetic and Semisynthetic Opioids01:15

Opioid Analgesics: Synthetic and Semisynthetic Opioids

Synthetic and semisynthetic opioids are pivotal in pain management and tackling opioid addiction. Semisynthetic opioids, including morphinans (morphine derivatives), oxycodone, oxymorphone, hydrocodone, and hydromorphone, have improved pharmacokinetic profiles compared to morphine. Additionally, heroin and 6-MAM (6-Monoacetylmorphine) show better CNS penetration than morphine due to heightened lipid solubility. Hydromorphone, a potent opioid, undergoes hepatic metabolism to form the active...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Palliative Pharmacotherapy: State-of-the-Art Management of Symptoms in Patients With Cancer.

Cancer control : journal of the Moffitt Cancer Center·2015
Same author

Pharmacological Management of Cancer-Related Pain.

Cancer control : journal of the Moffitt Cancer Center·2015
Same author

Palliative Oncologists: Specialists in the Science and Art of Patient Care.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2015
Same author

Fentanyl (transmucosal).

Journal of pain and symptom management·2012
Same author

Ketamine for pain: an update of uses in palliative care.

Journal of palliative medicine·2012
Same author

Octreotide.

Journal of pain and symptom management·2011
Same journal

Screening for substance use disorders in primary care settings: A systematic review.

Journal of opioid management·2026
Same journal

The prevalence of naloxone distribution and training programs at 4-year public colleges in the United States.

Journal of opioid management·2026
Same journal

The effect of a multifaceted intervention on post-operative opioid use after orthopedic and spine surgery: Results of a before-after pilot study.

Journal of opioid management·2026
Same journal

Post-operative opioid consumption after single-shot versus continuous erector spinae plane block in cardiac surgery: An observational study.

Journal of opioid management·2026
Same journal

Outcomes of patients with heart failure with preserved ejection frac-tion on chronic opioids: A nationwide analysis.

Journal of opioid management·2026
Same journal

Barriers providers face to prescribe buprenorphine as MOUD that can inform critical supports after the removal of the DATA-waiver.

Journal of opioid management·2026
See all related articles

Related Experiment Video

Updated: Jun 10, 2026

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
09:38

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Published on: April 14, 2016

Tapentadol: an initial analysis.

Eric E Prommer1

  • 1Department of Hematology/Oncology/Palliative Care, Mayo Clinic, Phoenix, Arizona, USA.

Journal of Opioid Management
|July 21, 2010
PubMed
Summary
This summary is machine-generated.

Tapentadol hydrochloride is a novel analgesic with dual action, offering potential for neuropathic pain management. Clinical trials show it has less potency than some opioids but minimal drug interactions.

More Related Videos

Dynamic Quantitative Sensory Testing to Characterize Central Pain Processing
09:16

Dynamic Quantitative Sensory Testing to Characterize Central Pain Processing

Published on: February 16, 2017

Related Experiment Videos

Last Updated: Jun 10, 2026

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery
09:38

Determining Pain Detection and Tolerance Thresholds Using an Integrated, Multi-Modal Pain Task Battery

Published on: April 14, 2016

Dynamic Quantitative Sensory Testing to Characterize Central Pain Processing
09:16

Dynamic Quantitative Sensory Testing to Characterize Central Pain Processing

Published on: February 16, 2017

Area of Science:

  • Pharmacology
  • Pain Management
  • Neuroscience

Background:

  • Tapentadol hydrochloride is a novel analgesic with a dual mechanism of action.
  • It acts as a mu-opioid receptor agonist and a norepinephrine reuptake inhibitor.
  • This dual action offers potential for synergistic analgesic effects and reduced opioid escalation.

Purpose of the Study:

  • To evaluate the analgesic properties of tapentadol hydrochloride.
  • To assess its potential in managing neuropathic pain.
  • To investigate its pharmacokinetic profile and drug interaction potential.

Main Methods:

  • Preclinical studies in acute and neuropathic pain models.
  • Human clinical trials in patients with nonmalignant pain.
  • Assessment of CYP 450 interactions.

Main Results:

  • Preclinical models confirmed analgesic properties in acute and neuropathic pain, though with lower potency than morphine.
  • Human trials indicated less potency than a step-3 opioid in nonmalignant pain.
  • Tapentadol demonstrated minimal CYP 450 interactions, suggesting a low potential for drug-drug interactions.

Conclusions:

  • Tapentadol hydrochloride presents a novel dual-action analgesic mechanism.
  • It shows promise for neuropathic pain management, with a favorable drug interaction profile.
  • Further clinical trials are needed to establish its efficacy in cancer pain and neuropathic pain populations.